Clinical trial
Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the…
NCT00073450 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00073450 |
|---|---|
| Title | Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530) |
| Official title | An Open-Label Phase 2 Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Squamous Cell, Head and Neck Neoplasms |
| Intervention type | Drug |
| Interventions | Farnesyl Protein Transferase Inhibitor |
| Enrollment | 15 |
| Start date | Sep 1, 2003 |
| Primary completion | Jun 1, 2004 |
| Completion | Jun 1, 2004 |
| First posted | Nov 24, 2003 |
| Last update posted | Apr 21, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: